Cargando…

Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy

Immunotherapy is a clinically validated treatment for many cancers to boost the immune system against tumor growth and dissemination. Several strategies are used to harness immune cells: monoclonal antibodies against tumor antigens, immune checkpoint inhibitors, vaccination, adoptive cell therapies...

Descripción completa

Detalles Bibliográficos
Autores principales: Mollica Poeta, Valeria, Massara, Matteo, Capucetti, Arianna, Bonecchi, Raffaella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414456/
https://www.ncbi.nlm.nih.gov/pubmed/30894861
http://dx.doi.org/10.3389/fimmu.2019.00379
_version_ 1783402979133489152
author Mollica Poeta, Valeria
Massara, Matteo
Capucetti, Arianna
Bonecchi, Raffaella
author_facet Mollica Poeta, Valeria
Massara, Matteo
Capucetti, Arianna
Bonecchi, Raffaella
author_sort Mollica Poeta, Valeria
collection PubMed
description Immunotherapy is a clinically validated treatment for many cancers to boost the immune system against tumor growth and dissemination. Several strategies are used to harness immune cells: monoclonal antibodies against tumor antigens, immune checkpoint inhibitors, vaccination, adoptive cell therapies (e.g., CAR-T cells) and cytokine administration. In the last decades, it is emerging that the chemokine system represents a potential target for immunotherapy. Chemokines, a large family of cytokines with chemotactic activity, and their cognate receptors are expressed by both cancer and stromal cells. Their altered expression in malignancies dictates leukocyte recruitment and activation, angiogenesis, cancer cell proliferation, and metastasis in all the stages of the disease. Here, we review first attempts to inhibit the chemokine system in cancer as a monotherapy or in combination with canonical or immuno-mediated therapies. We also provide recent findings about the role in cancer of atypical chemokine receptors that could become future targets for immunotherapy.
format Online
Article
Text
id pubmed-6414456
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64144562019-03-20 Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy Mollica Poeta, Valeria Massara, Matteo Capucetti, Arianna Bonecchi, Raffaella Front Immunol Immunology Immunotherapy is a clinically validated treatment for many cancers to boost the immune system against tumor growth and dissemination. Several strategies are used to harness immune cells: monoclonal antibodies against tumor antigens, immune checkpoint inhibitors, vaccination, adoptive cell therapies (e.g., CAR-T cells) and cytokine administration. In the last decades, it is emerging that the chemokine system represents a potential target for immunotherapy. Chemokines, a large family of cytokines with chemotactic activity, and their cognate receptors are expressed by both cancer and stromal cells. Their altered expression in malignancies dictates leukocyte recruitment and activation, angiogenesis, cancer cell proliferation, and metastasis in all the stages of the disease. Here, we review first attempts to inhibit the chemokine system in cancer as a monotherapy or in combination with canonical or immuno-mediated therapies. We also provide recent findings about the role in cancer of atypical chemokine receptors that could become future targets for immunotherapy. Frontiers Media S.A. 2019-03-06 /pmc/articles/PMC6414456/ /pubmed/30894861 http://dx.doi.org/10.3389/fimmu.2019.00379 Text en Copyright © 2019 Mollica Poeta, Massara, Capucetti and Bonecchi. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Mollica Poeta, Valeria
Massara, Matteo
Capucetti, Arianna
Bonecchi, Raffaella
Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy
title Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy
title_full Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy
title_fullStr Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy
title_full_unstemmed Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy
title_short Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy
title_sort chemokines and chemokine receptors: new targets for cancer immunotherapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414456/
https://www.ncbi.nlm.nih.gov/pubmed/30894861
http://dx.doi.org/10.3389/fimmu.2019.00379
work_keys_str_mv AT mollicapoetavaleria chemokinesandchemokinereceptorsnewtargetsforcancerimmunotherapy
AT massaramatteo chemokinesandchemokinereceptorsnewtargetsforcancerimmunotherapy
AT capucettiarianna chemokinesandchemokinereceptorsnewtargetsforcancerimmunotherapy
AT bonecchiraffaella chemokinesandchemokinereceptorsnewtargetsforcancerimmunotherapy